Adtran’s Coherent 100ZR and FSP 3000 OLS to play key role in OIF’s ECOC open interoperability showcase
20.9.2024 15:00:00 EEST | Business Wire | Press release
Adtran today announced its key role in the Optical Internetworking Forum’s (OIF) demonstration of open, multi-vendor networking at the European Conference on Optical Communication (ECOC) 2024. At the center of the showcase are Adtran’s Coherent 100ZR QSFP28 pluggable module and its FSP 3000 open optical line system (OLS), which enables the transport of a wide range of data rates, including 100ZR and 400Gbit/s OpenZR+, as featured in this demo. Incorporating 100Gbit/s to 800Gbit/s coherent pluggable transceivers and various OLS technologies from multiple vendors, the demo showcases advancements in open optical networking and innovative vendor-neutral solutions, highlighting the importance of testing multi-vendor interoperability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920990844/en/
Adtran’s central role in the OIF demo underlines its commitment to developing open solutions that seamlessly interoperate with other vendors. (Photo: Business Wire)
“Adtran continues to lead the way in promoting open, disaggregated networking. By integrating our FSP 3000 OLS with 100ZR and 400Gbit/s OpenZR+ transceivers from a wide range of vendors, including our coherent 100ZR QSFP28, we’re offering operators a cost-effective, low-power solution to enhance their data center interconnect (DCI) networks and cloud infrastructure. With its standards-compliant design, our coherent 100ZR facilitates multi-vendor interoperability for 100Gbit/s transmission up to 300km over any open line system, while the FSP 3000 OLS streamlines operations and ensures flexible, scalable transport with optimal performance,” said Christoph Glingener, CTO of Adtran. “This collaboration with the OIF and other major industry players demonstrates our commitment to providing open solutions that meet the evolving demands of the cloud and the optical edge.”
The joint solution on display showcases exceptional optical performance, with the Adtran FSP 3000 OLS ensuring streamlined setup and precise operation. Equipped with integrated monitoring and diagnostic functions, as well as a high level of automation, the FSP 3000 OLS simplifies management and optimizes transmission performance. The collaboration with industry leaders highlights Adtran’s commitment to open optical networking solutions and demonstrates how its technology is built to industry standards. This approach offers the flexibility and scalability needed to meet diverse customer requirements while advancing multi-vendor interoperability.
“For decades, we’ve been pioneers in the DCI space, enabling enterprises and cloud providers to build high-capacity, high-performance networks. Our solutions are built around an open environment, promoting innovation and seamless interoperability with other vendors. We’re proud to be at the heart of this large-scale demonstration, where our Coherent 100ZR and FSP 3000 OLS are driving the adoption of open, multi-vendor interoperability for data center applications,” commented Stephan Neidlinger, VP of global business development at Adtran. “By championing openness and collaboration across the industry, we’re advancing high-performance networking and reaffirming our leadership in delivering the technologies that will shape the future of optical networking.”
Visitors to ECOC can find out more about the demo at Adtran’s booth, D79, and the OIF’s booth, B83.
OIF Champions Interoperability at ECOC 2024: 34 Member Companies to Showcase Solutions for Data Centers, AI/ML Technologies and Disaggregated Systems
At ECOC 2024, OIF will host a dynamic interoperability demonstration, featuring live collaboration from 34 member companies shaping the future of connectivity. This showcase will highlight advanced solutions that are redefining performance, efficiency and capacity in response to the burgeoning needs of future-oriented data centers, AI/ML technologies and disaggregated systems. Attendees will discover cutting-edge interoperability solutions in 800ZR, 400ZR and Multi-span optics, along with innovations in Energy Efficient Interfaces (EEI) & Co-Packaging, 224G and 112G Common Electrical I/O (CEI) and Common Management Interface Specification (CMIS) that are crucial for shaping the next decade of industry standards. Visit us at booth #B83 for live, interactive demonstrations. For further details, please visit: https://www.oiforum.com/meetings-events/oif-ecoc-2024.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240920990844/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Rhonda Lambert
+1 256 963 7450
investor.relations@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom